ГИСТОЛОГИЧЕСКИЕ И УЛЬТРАСТРУКТУРНЫЕ ИЗМЕНЕНИЯ ТОНКОГО КИШЕЧНИКА ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ
Ключевые слова:
ультраструктуравий ўзгаришлар, ингичка ичак, метаболик синдром, энтероцитлар, микроциркуляция, яллиғланиш, гипоксия, инсулинга резистентликАннотация
Метаболический синдром (МС) оказывает значительное влияние на морфофункциональное состояние тонкого кишечника, приводя к выраженным гистологическим и ультраструктурным изменениям. В статье рассматриваются основные патологические процессы, включая дестабилизацию эпителиального барьера, гипоксию, воспалительные реакции и нарушение микроциркуляции. Особое внимание уделено изменениям энтероцитов, таких как повреждение митохондрий, нарушение межклеточных контактов и увеличение сосудистой проницаемости. Данные изменения способствуют развитию кишечной дисфункции, усиливая системные проявления метаболического синдрома.
Библиографические ссылки
Ahmad R. et al. Obesity-induces organ and tissue specific tight junction restructuring and barrier deregulation by claudin switching //Scientific reports. – 2017. – Т. 7. – №. 1. – С. 1-16.
Aidarbekova D. et al. A Longitudinal Assessment of Metabolic Syndrome //Journal of Clinical Medicine. – 2025. – Т. 14. – №. 3. – С. 747.
Antony P. et al. Prevalence of Metabolic Syndrome and Its Association With Clinical Correlates and Caregiver Burden in Patients With Bipolar Disorder at a Tertiary Hospital //Cureus. – 2024. – Т. 16. – №. 10.
Aoqui C. et al. Microvascular dysfunction in the course of metabolic syndrome induced by high-fat diet //Cardiovascular Diabetology. – 2014. – Т. 13. – С. 1-11.
Biswas J. et al. (ed.). Inflammation-Volume 1-2020. – ChanRe Publishers, 2021.
Biswas K. et al. Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia: a narrative review //Journal of Current Medical Research and Opinion. – 2021. – Т. 4. – №. 03. – С. 867-877.
Burcelin R. Gut microbiota and immune crosstalk in metabolic disease //Molecular metabolism. – 2016. – Т. 5. – №. 9. – С. 771-781.
Chae Y. R. et al. Diet-induced gut dysbiosis and leaky gut syndrome //Journal of Microbiology and Biotechnology. – 2024. – Т. 34. – №. 4. – С. 747.
Chen C. L., Lin Y. C. Autophagy dysregulation in metabolic associated fatty liver disease: A new therapeutic target //International journal of molecular sciences. – 2022. – Т. 23. – №. 17. – С. 10055.
Collado A. et al. Functional role of endothelial CXCL16/CXCR6-platelet–leucocyte axis in angiotensin II-associated metabolic disorders //Cardiovascular Research. – 2018. – Т. 114. – №. 13. – С. 1764-1775.
COZMA¹ A. et al. Endothelial dysfunction in metabolic syndrome //Rom J Intern Med. – 2009. – Т. 47. – №. 2. – С. 133-40.
de Souza P. A. Metabolic syndrome as the main risk factor associated with the development of type 2 Diabetes Mellitus and cardiovascular pathologies //Brazilian Journal of Clinical Medicine and Review. – 2024. – Т. 2. – №. 4. – С. 23-33.
Dhondge R. H. et al. A comprehensive review of metabolic syndrome and its role in cardiovascular disease and type 2 diabetes mellitus: Mechanisms, risk factors, and management //Cureus. – 2024. – Т. 16. – №. 8.
Fahed G. et al. Metabolic syndrome: updates on pathophysiology and management in 2021 //International journal of molecular sciences. – 2022. – Т. 23. – №. 2. – С. 786.
Fändriks L. Roles of the gut in the metabolic syndrome: an overview //Journal of internal medicine. – 2017. – Т. 281. – №. 4. – С. 319-336.
Feakins R. M. Obesity and metabolic syndrome: pathological effects on the gastrointestinal tract //Histopathology. – 2016. – Т. 68. – №. 5. – С. 630-640.
Ghorbani Z. et al. Supplementing the standard diet with brown rice bran powder might effectively improve the metabolic syndrome characteristics and antioxidant status: an open label randomized controlled trial //Food & Function. – 2025. – Т. 16. – №. 2. – С. 750-762.
Gueddouri D. et al. Insulin resistance per se drives early and reversible dysbiosis-mediated gut barrier impairment and bactericidal dysfunction //Molecular metabolism. – 2022. – Т. 57. – С. 101438.
Jahn L. A. et al. Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome //American Journal of Physiology-Endocrinology and Metabolism. – 2022. – Т. 322. – №. 2. – С. E173-E180.
Januario E. et al. A Comprehensive Review of Pathophysiological Link Between Non-alcoholic Fatty Liver Disease, Insulin Resistance, and Metabolic Syndrome //Cureus. – 2024. – Т. 16. – №. 12.
Khaldoun S. A. et al. Autophagosomes contribute to intracellular lipid distribution in enterocytes //Molecular biology of the cell. – 2014. – Т. 25. – №. 1. – С. 118-132.
Kim Y. S., Ho S. B. Intestinal goblet cells and mucins in health and disease: recent insights and progress //Current gastroenterology reports. – 2010. – Т. 12. – С. 319-330.
Kvit K. B., Kharchenko N. V. Small intestinal bacterial overgrowth in the intestine and microbiome alterations as a risk factor for lipid metabolism disorders in patients with nonalcoholic fatty liver disease //Art of Medicine. – 2024. – С. 38-44.
Lei W. et al. Activation of intestinal tuft cell-expressed Sucnr1 triggers type 2 immunity in the mouse small intestine //Proceedings of the National Academy of Sciences. – 2018. – Т. 115. – №. 21. – С. 5552-5557.
Lemieux I., Després J. P. Metabolic syndrome: past, present and future //Nutrients. – 2020. – Т. 12. – №. 11. – С. 3501.
Magne F. et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? //Nutrients. – 2020. – Т. 12. – №. 5. – С. 1474.
Papila, Berrin. "Association of Metabolic Syndrome with Gastrointestinal Disorders." Metabolic Syndrome: A Comprehensive Update with New Insights. Bentham Science Publishers, 2025. 69-83.
Petri M. et al. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists //Journal of Diabetes and its Complications. – 2021. – Т. 35. – №. 2. – С. 107733.
Ruan Y. et al. Tingli Dazao Xiefei Decoction ameliorates asthma in vivo and in vitro from lung to intestine by modifying NO–CO metabolic disorder mediated inflammation, immune imbalance, cellular barrier damage, oxidative stress and intestinal bacterial disorders //Journal of Ethnopharmacology. – 2023. – Т. 313. – С. 116503.
Sharifnia T. et al. Hepatic TLR4 signaling in obese NAFLD //American Journal of Physiology-Gastrointestinal and Liver Physiology. – 2015. – Т. 309. – №. 4. – С. G270-G278.
Somabattini R. A. et al. Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions //Life Sciences. – 2024. – С. 122806.
Suriano F. et al. Fat and not sugar as the determining factor for gut microbiota changes, obesity, and related metabolic disorders in mice //American Journal of Physiology-Endocrinology and Metabolism. – 2023. – Т. 324. – №. 1. – С. E85-E96.
Sypniewska G. Pro-inflammatory and prothrombotic factors and metabolic syndrome //EJIFCC. – 2007. – Т. 18. – №. 1. – С. 39.
Tziomalos K. et al. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management //Nutrition, Metabolism and Cardiovascular Diseases. – 2010. – Т. 20. – №. 2. – С. 140-146.
Valencia I. et al. Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus //Cardiovascular Diabetology. – 2024. – Т. 23. – №. 1. – С. 75.
Wang M. et al. Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients //Clinical Immunology. – 2018. – Т. 197. – С. 77-85.
Zietek T., Rath E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1 //Frontiers in immunology. – 2016. – Т. 7. – С. 154.
Rizaev JA, Khazratov AI, Iordanishvili AK Morphofunctional characteristics of the mucous membrane of the masticatory apparatus in experimental carcinogenesis //Russian Journal of Dentistry. – 2021. – T. 25. – No. 3. – pp. 225-231.
